Pure Global
NCT06394063

Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients

A Randomized, Double-blind, Placebo-controlled Trial of Efficacy and Safety of Low-dose Telitacicept for Prevention of Flares in SLE Patients With Low Disease Activity
RenJi Hospital·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Systemic Lupus Erythematosus
Drug/Device/Intervention
Telitacicept
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
RenJi Hospital
Timeline & enrollment
Phase
N/A
Start date
Jun 30, 2024
End date
Jun 30, 2027
Enrollment
176 participants
Primary outcome

Percentage of patients with disease flares

Summary

This study is a randomized, double-blind, placebo-controlled single-center clinical trial.
 The aim of this study is to investigate the efficacy and safety of low-dose telitacicept for
 prevention of flares in SLE patients with low disease activity.

ICD-10 classifications
Systemic lupus erythematosusSystemic lupus erythematosus, unspecifiedLupus erythematosusSystemic lupus erythematosus with organ or system involvementOther forms of systemic lupus erythematosus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06394063
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06394063 through Pure Global AI's free database. This phase not specified trial is sponsored by RenJi Hospital and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 176 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.